Status Quo: US Approvals For Pepaxto, Copiktra Remain Intact Despite Negative Panel Reviews

 
• By Sue Sutter
  
Thumbs down
Pepaxto and Copiktra were knocked down at a September ODAC meeting, but they're still not completely out. • Source: Shutterstock

More from Post-Marketing Regulation & Studies

More from Product Reviews